VisioCyt® allows an earlier diagnosis of bladder cancer from a simple urine sample.
This innovative solution is based on a patented technology combining fluorescence imaging and artificial intelligence.
VisioCyt® obtained the CE mark in January 2020.
The VisioCyt® 1 clinical trial started in January 2017. This trial was conducted in collboration with 14 French hospitals and included 1360 patients.
The goal is to evaluate the diagnostic perfomances of VisioCyt® in the event of a bladder tumor suspicion.
VitaDX has developed an innovative solution for the early diagnosis of bladder cancer, based on a patented technology combining fluorescence imaging and artificial intelligence. VitaDX leverages research work, carried out by researchers from the Institut des Sciences Moléculaires d'Orsay (ISMO, UMR CNRS and Université Paris-Sud) and practitioners from the Kremlin Bicêtre hospital (AP-HP) whose goal was to diagnose bladder cancer earlier to optimise patient care.
35000 Rennes, France
75015 Paris, France